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Abstract 32 
Synkinesis is a distressing sequela of peripheral facial palsy (PFP). This study aimed to 33 
translate and validate the Synkinesis Assessment Questionnaire (SAQ), a reliable patient-34 
reported outcome evaluation tool for synkinesis, in French. 35 
The SAQ was translated following a standard forward-backward translation procedure. After a 36 
cognitive debriefing with 10 PFP patients, the SAQ-F was assessed amongst 50 patients for 37 
internal consistency, known-group validity, construct validity, criterion validity and test-retest 38 
reliability. 39 
Results demonstrated that the SAQ-F was valid, reliable and had a unidimensional structure. 40 
The SAQ-F should be accompanied by clinician-based scales, to provide valuable additional 41 
information on the severity of synkinesis. 42 
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Facial synkinesis is among the most invalidating consequences of peripheral facial palsy (PFP). 43 
It is defined as abnormal muscle contractions of one or many facial areas during volitional facial 44 
movement1. Synkinesis has numerous functional and cosmetic adverse effects as it limits 45 
several day-to-day activities like speaking and eating2. Potential mechanisms for the 46 
development of synkinesis could be due to aberrant reinnervation, either by stimulation of 47 
neighbor axons in the context of myelin loss or due to hyperexcitability of the facial nucleus1. 48 
From a research perspective, the use of a validated universal grading system for synkinesis 49 
would allow appropriate data pooling and help in establishing valid recommendations for clinical 50 
decision making3. From a clinical perspective, the evaluation of synkinesis through a patient-51 
reported outcome measure (PROM) is critical to grasp the scope of the handicap that it causes4. 52 
Observer-based evaluation of facial function often leads to an incomplete description of patient 53 
psychological distress and functional impairments that are caused by the sequelae of facial 54 
palsy5.  55 
The Synkinesis Assessment Questionnaire (SAQ)2 was developed as a specific and validated 56 
PROM for synkinesis. While the original English version has demonstrated to be a reliable and 57 
valid instrument, there is no existing French equivalent. The purpose of the present study was to 58 
create a validated French version of the SAQ in accordance with international guidelines of 59 
translation and cultural adaptation. 60 
  61 
The present study was approved by the ethics review board of the Centre-intégré-universitaire-62 
de-santé-et-de-services du Nord-de-l’Île-de-Montréal (MP-32-2020-1952). Written informed 63 
consent was obtained from all participants. 64 
https://doi.org/10.1017/cjn.2020.208
Downloaded from https://www.cambridge.org/core. Universite de Montreal, on 22 Sep 2020 at 13:38:28, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
The translation and cultural validation process respected international guidelines3. A standard 65 
forward and backward-translation procedure was adopted, with two independent certified 66 
translators who produced distinct translations from the original to the target language. Those 67 
two translations were merged by the senior researcher of the study. A third translator back-68 
translated the reconciled version for review and identification of discrepancies.  69 
The preliminary version was administered by the first author to 10 native French patients with 70 
PFP (women: 8; mean age: 47.4 (15.6)) for cognitive debriefing3. Appropriate minor changes 71 
were then made to the preliminary version and the resulting French version of the SAQ (SAQ-F) 72 
was used for validation (Figure 1). 73 
Validation of SAQ-F was conducted with a prospective cohort study including 25 patients with 74 
PFP and 25 controls who visited the Otolaryngology clinic for other indications than a PFP (ear 75 
infection, dysphonia, tonsillitis, etc.), from February to April 2020. Inclusion criteria were having 76 
a PFP and being 18 years old and older. Exclusion criteria were: 1) history of neurological 77 
disorders; 2) active psychiatric disease; 3) cognitive disorder; 4) inability to understand written 78 
and oral French. For the PFP participants, the severity of facial palsy was assessed using the 79 
Facial Nerve Grading System 2.0 (FNGS 2.0; also known as the House-Brackmann 2.0 score)6 80 
and the Sunnybrook Facial Grading System (SB)7. These were chosen because each has been 81 
shown to have high inter-observer agreement and validity8. Specific subscores of synkinesis can 82 
be calculated from either scale to allow for more specific analyses. Patients completed the SAQ-83 
F twice within a two-week interval for test-retest reliability. None of the PFP patients were 84 
subject to changes in their treatment. 85 
Of 50 respondents, 25 were PFP patients and 25 controls (Table 1), with 20 men (40%) and 30 86 
women (60%). The average age was 51.6 (18.4) years for the entire sample, 52.7 (18.6) years 87 
in PFP and 50.6 (18.4) years in controls. The mean total SAQ score was 18.5 (95% CI 15.7 to 88 
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21.2, median 17, range 17-34) points in PFP group, and 9.0 (no variance) points in controls with 89 
a difference of -9.5 (95% CI -12.2 to -6.8) points. and p-value <0.0001. Of the PFP patients, 90 
80% were diagnosed with Bell’s palsy and the remaining 20% were diagnosed with a PFP 91 
secondary to Ramsay-Hunt’s Syndrome, facial nerve schwannoma or traumatic injury. Severity 92 
of facial palsy was generally rated as light to moderate with both FNGS 2.0 and SB scales: 93 
mean FNGS 2.0 score was 9.4 (4.2) and mean SB score was 73.5 (21.5). 94 
 95 
The analyses were performed using Stata/IC Statistical Software: Release 16. College Station 96 
(StataCorp LP, TX, USA). The internal consistency of SAQ-F was assessed by using a 97 
Chronbach’s alpha along with its lower 95% confidence limit (95% CL). Alpha ≥ 0.9 was 98 
considered excellent, ≥0.8 good, ≥0.7 acceptable, ≥0.6 questionable and ≥0.5 poor. The known-99 
group validity (PFP vs. controls) was assessed by using a t-test for independent groups in case 100 
of total score, and the Kruskal-Wallis nonparametric test for the items’ ordinal scores. A two-101 
tailed p-value ≤ 0.05 was considered statistically significant. The test-retest validity of the SAQ-F 102 
scale was assessed by employing a Spearman rank correlation coefficient. Exploratory factor 103 
analysis (EFA) was used to approximate the construct structure of the SAQ-F and included only 104 
PFP patients. The goal was to determine whether the SAQ-F measures only one latent trait (= 105 
signs of facial paralysis) or if there are other possible significant latent variables affecting the 106 
results. The results were analyzed graphically. After the orthogonal varimax rotation was 107 
applied, retained and excluded factors were explored visually on a scree plot along with a 108 
parallel analysis. Pearson's product-moment correlation was used when comparing the SAQ-F 109 
total score with the synkinesis subscores obtained from the Sunnybrook and FNGS 2.0 scales. 110 
Fisher's transformation was used for both Spearman and Pearson’s tests. Correlation <0.2 was 111 
considered poor, from 0.21 to 0.4 fair, from 0.41 to 0.6 moderate, from 0.61 to 0.8 substantial, 112 
and >0.8 perfect. 113 
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 Results showed that the internal consistency of the SAQ-F was good with alpha of 0.87 (lower 114 
95% CL 0.82). Results of the test-retest reliability were substantial to perfect for the total score 115 
as well as for all nine items individually (0.96, 95% CI 0.93 to 0.98) (Table 2). Known-group 116 
validity of SAQ-F appeared to be high as there were significant differences between groups in 117 
the total score and in seven out of nine items’ scores (p<0.01) (Table 3). Construct validity of 118 
the SAQ-F was tested by an exploratory factor analysis (Table 4 and Figure 2). The parallel 119 
analysis of the scree plot showed that SAQ-F had three factors with positive eigenvalues above 120 
the parallel analysis line. However, the eigenvalues of the second and third factors were as low 121 
as 1.2 and 0.6 respectively and were disregarded for retaining. Thus, the SAQ-F was 122 
considered to have a unidimensional structure with one factor, whose eigenvalue was 3.1. 123 
When assessing the criterion validity based on the 25 PFP patients, Pearson's product-moment 124 
correlation of the SAQ-F total score and the FNGS 2.0 synkinesis subscore was not significant 125 
(r=-0.23; 95% CI: -0.57 to 0.18). The Spearman's rank correlation of SAQ-F total score with 126 
Sunnybrook synkinesis subscore was also not significant (r=-0.19; 95% CI: -0.55 to 0.22). 127 
In this study, we presented the translation and validation of the SAQ-F, a French patient-128 
centered questionnaire based on the original English SAQ2.The SAQ scale allows to quantify 129 
the patient’s perception of synkinesis’ severity and thus allows to adapt the management and 130 
overall care of synkinesis, to fit the patient's expectations. Cross-cultural adaptation and 131 
validation is necessary in the use of PROM questionnaires, to avoid misinterpretation while 132 
using questionnaires developed in other countries3. To our knowledge, no other study validated 133 
the SAQ scale in French. Thus, the SAQ-F will be highly relevant for many clinical and research 134 
settings in Quebec and other French-speaking regions. 135 
We translated and validated the SAQ-F according to the best practice’s international 136 
guidelines3. Our results showed that the SAQ-F has good internal consistency, a high test-retest 137 
reliability, a high known-group validity, allowing to distinguish between controls and PFP 138 
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patients, as well as good construct validity. Compared to the original version, the SAQ-F 139 
presented a slightly higher internal consistency (0.87 for SAQ-F and 0.80 for SAQ) and test-140 
retest reliability (0.96 in our study and 0.881 in the original one).  141 
Correlations with synkinesis subscores of clinician-based questionnaires were not significant. 142 
Other studies already reported discrepancies between PROM and clinician-based physical 143 
examination5. A high correlation between both measures is probably not to be expected, and 144 
both of them should be taken for a complete overview of the synkinesis severity2,1.  145 
This study is not without limitation. As the data comes from a small number of patients, non-146 
significant results regarding criterion validity could be due to lack of power. Due to practical 147 
reasons, the group size was limited to 25 patients, which is nonetheless comparable with many 148 
other PROM studies in the literature about PFP9. Further research may reveal valuable 149 
information about SAQ-F psychometric properties by employing, for example, item response 150 
theory analysis (IRT)10.  151 
The SAQ-F was found to be a reliable, easy-to-use and valid unidimensional scale to assess 152 
synkinesis after PFP. The SAQ-F should be accompanied by clinician-based scales to provide 153 
valuable additional information on the severity of synkinesis.  154 
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Figure Captions:  162 
 163 
Figure 1. Synkinesis Assessment Questionnaire- French 164 
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Table 1. Patients demographics  
  
Controls PFP patients 




    Male 
 
 
    Female 
   
11 44 
 
   9 36 
 
   
14 56 
 
   16 64 
 
   
Age (years) 
 
 50.6 18.4 56 23-90 
 
 52.7 18.6 53 19-95 
Diagnosis 





   Ramsay  
     Hunt 
   
 Facial nerve   
  Schwannoma 
 
   Traumatic  
        injury 
 
           
 
     20 80 
 
   
      2 8 
 
   
      2 8 
 
   
      1 4 
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Side 
 
           
   Left 
 
     11 44 
 
   
   Right 
 
     14 56 
 
   
FNGS 2.0 total 
score  
       9.44 4.2 9 9-24 
Sunnybrook 
total score  
       73.5 21.5 76 5-97 
SAQ-F total 
score  
 9 0 9 9 
 
 18.5 17 17 34 
 
Note: PFP= peripheral facial palsy; n = number; SD = standard deviation; Facial Nerve Grading Scale 2.0 (FNGS 2.0) scores: 24 = 
total palsy; 4 = no facial palsy. Sunnybrook (SB) scores: minimum possible = 0 or total palsy; maximum possible = 100% or normal; 
SAQ scores: 9 = no synkinesis; 45 = severe synkinesis. 
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Table 2. Test-retest validity of the SAQ-F (including both PFP and control groups) 
  
r 95%CI 
Lower limit vs upper limit 
Total score 0.96 0.93 0.98 
Item 1 0.78 0.65 0.87 
Item 2 0.92 0.87 0.96 
Item 3 0.93 0.88 0.96 
Item 4 0.92 0.85 0.95 
Item 5 0.69 0.51 0.81 
Item 6 0.90 0.82 0.94 
Item 7 0.60 0.38 0.75 
Item 8 0.89 0.81 0.94 
Item 9 0.81 0.69 089 
  
Note: SAQ-F= Synkinesis Assessment Questionnaire – French; PFP = peripheral facial palsy; 
CI = confidence interval . 
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Table 3. Know-group validity – differences in SAQ-F scores between PFP and control groups. 
  p-value 
Total score <0.0001 a 
Item 1 0.0002 b 
Item 2 0.0015 b 
Item 3 0.0006 b 
Item 4 0.0033 b 
Item 5 0.0015 b 
Item 6 0.0001 b 
Item 7 0.0500 b 
Item 8 0.0041 b 
Item 9 0.2207 b 
Note:  a Independent groups t-test; b Kruskal-Wallis test; SAQ-F= Synkinesis Assessment 
Questionnaire – French; PFP = peripheral facial palsy; CI = confidence interval . 
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Table 4. Rotated factor loadings (pattern matrix) and unique variances 
Factors → 
Variable ↓ 
1 2 3 4 5 Uniqueness 
Item 1 0.10 0.28 0.70 0.02 0.00 0.42 
Item 2 0.10 0.87 0.21 -0.10 -0.09 0.16 
Item 3 0.19 0.88 0.01 0.08 0.12 0.17 
Item 4 0.68 0.12 0.44 0.13 0.08 0.30 
Item 5 0.74 0.33 0.09 -0.04 0.08 0.33 
Item 6 0.54 0.40 0.13 0.01 0.28 0.45 
Item 7 0.84 0.05 -0.05 0.01 -0.07 0.28 
Item 8 0.03 -0.15 0.05 -0.34 -0.01 0.86 
Item 9 0.13 -0.18 0.19 0.44 0.01 0.72 
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